Autopsy report · NCT04445389

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

“The sponsor decided to change the investigational product for a strategic reason.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 60 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Genexine, Inc.

Sponsor type

Industry

Conditions

SARS-CoV-2

Interventions

GX-19; Saline

Participants

60

Sites

1

Countries

South Korea

Trials that died the same way

• Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
  “Sponsor no longer pursuing regulatory approval of investigational device” (68% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (68% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (67% match in meaning)
• Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
  “sponsor and investigator 's decision” (66% match in meaning)
• Study to Optimize the IOL Constant of a New Multifocal Intraocular Lens
  “Sponsor decided to modify the prototype device used in study” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.